FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Healthcare & Life Sciences Venture Capital Monitor – USA – 04/2024”.
The Monitor is a monthly published overview of venture capital trends in the US Healthcare & Life Sciences sector.
As of the end of April 2024 we identified the following current VC trends in the United States:
Total Healthcare & Life Sciences funding reached EUR 11,689m
Biotech received 66% (including 8% via the funding of Xaira Therapeutics) of the total investment volume (EUR 7,702m) with oncology being the leading indication (28%)
In April the Digital Therapy Development Company Xaira Therapeutics secures the highest transaction volume with EUR 930m, followed by Metsera with EUR 322m and Cerevance with EUR 152m
ARCH Venture Partners (United States) is the most active investor (by deal volume), followed by RA Capital Management (United States) and F-Prime Capital (United States)
To access the full report, please click here.By Mathias Klozenbücher und Johannes Link.
